Breaking News
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
February 16, 2019 - Conformance of genetic characteristics found to be crucial for longer preservation of kidney graft
February 16, 2019 - Researchers use optogenetic tool to control, visualize receptor signals in neural cells
February 16, 2019 - New reversible antiplatelet therapy could reduce risk of blood clots, prevent cancer metastasis
February 16, 2019 - Testosterone is not the only hormone needed for penis development
February 16, 2019 - FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression
February 15, 2019 - Heart surgery technology developed at Baptist Health debuts after years of secrecy
February 15, 2019 - Prescription Opioids Double Risk of Triggering Fatal Car Crash
February 15, 2019 - New study helps doctors better understand high blood pressure in pregnant women
February 15, 2019 - Beta wave control in Parkinson’s diseased brain could be a potential therapy
February 15, 2019 - Media representations of love may justify gender-based violence in young people
February 15, 2019 - Yoga May Help With Rheumatoid Arthritis Symptoms, Severity
February 15, 2019 - Obstructive sleep apnea linked to inflammation, organ dysfunction
February 15, 2019 - Master your mind: A challenge from WELL for Life
February 15, 2019 - Why Some Brain Tumors Respond to Immunotherapy
February 15, 2019 - Must-Reads Of The Week From Brianna Labuskes
February 15, 2019 - Researchers uncover novel mechanism and potential new therapeutic target for Alzheimer’s
February 15, 2019 - Genetic variations in a fourth gene associated with higher ALL risk in Hispanic children
February 15, 2019 - Disruptive behavioral problems in kindergarten linked with lower employment earnings in adulthood
February 15, 2019 - New bioengineered device enhances the production of T-cells
February 15, 2019 - HDL proteome behaves like a tiny Velcro ball that is rolling on surfaces
February 15, 2019 - Puerto Rican children more likely to have poor or decreasing use of asthma inhalers
February 15, 2019 - Quality of patient care does not improve after physician-hospital integration
February 15, 2019 - Synopsys release new software for implant design and patient-specific planning
Professor Jean-Charles Soria granted award for pioneering role in cancer drug development

Professor Jean-Charles Soria granted award for pioneering role in cancer drug development

image_pdfDownload PDFimage_print

The TAT 2018 Honorary Award for cancer drug development has been granted to Professor Jean-Charles Soria, for his pioneering role in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy. The award will be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2018, to be held in Paris, France, 5-7 March.

The TAT Honorary Award was established in the early 1990s to acknowledge distinguished cancer drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.

Over the past 15 years, Soria has pushed forward the molecular enrichment of patient populations in early clinical trials. This has increased response rates and been a key factor in the successful development of a number of drugs, including osimertinib for lung cancer. He has launched large precision medicine trials in both early drug development and lung cancer.

In the immunotherapy field, Soria has contributed to first-in-man trials of atezolizumab and pembrolizumab, which have changed the treatment of cancer. He was deeply committed to obtaining paired tumour biopsies for a better understanding of the mechanism of action of anti PD(L)1 antibodies. He has promoted awareness of the unique toxicity profile of immunotherapies which can exhibit late side effects of a unique profile.

Soria was Editor-in-Chief of ESMO’s flagship scientific journal Annals of Oncology from 2014 to 2017. Under his leadership the journal reached an impact factor of 11.588, demonstrating his commitment to educating doctors and promoting new discoveries in cancer treatment and strengthening ESMO’s position as the driver of “Good science. Better medicine. Best practice.”

Soria said: “I am extremely happy to receive this award at a time when ESMO is taking over the organization of the TAT Congress, which is ‘the home of phase I oncology’. ESMO will provide this unique meeting the opportunity to grow and motivate more clinicians and scientists to understand and become passionate about drug development.”

In his TAT 2018 Honorary Award Keynote Address, Soria will outline how the drug development paradigm has changed over the past ten years. He said: “We have evolved from a classical drug development paradigm, which was a sequence of phase I, II, and III trials, to a situation where we now distinguish early drug development, encompassing phase I/II trials of registrational value and hundreds of patients, and late drug development, which is mainly phase III trials.”

In early drug development, the focus is no longer on just safety/toxicity but also activity and biomarkers of response, and early drug development trials include a much bigger number of patients (up to a thousand). “The registration value of phase I trials, which was null before, is real and can lead to breakthrough designation and conditional approval,” he said. “This change in paradigm has accelerated the development of new anticancer treatment for the benefit of cancer patients.”

The reasons underlining this transition include the advent of precision medicine and use of molecular targeted agents in selected populations. This approach has led to trial enrichment and increased response rates, which regulators consider a potential outcome for registration. The advent of immunostimulatory antibodies has also fostered a completely new type of early drug development trials with implementation of large organ-specific parallel expansion cohorts.

Soria said: “This new paradigm creates a number of opportunities and challenges. Optimising drug development for immunotherapies, targeted agents and modern chemotherapies is key, especially when accounting for the clear need to combine them for cancer control.” Finally, Soria said: “This is a strong recognition of a 15-year expanse in my career focusing on bringing new medicines to clinical practice for the benefit of cancer patients. It is emotionally an important award to me because early drug development is an area with few accolades. And therefore, to receive the TAT 2018 Honorary Award, reflects a stringent selection process.”

Source:

http://www.esmo.org/Press-Office/Press-Releases/Cancer-Drug-Development-Award-Given-to-Jean-Charles-Soria

Tagged with:

About author

Related Articles